Nanobiotix突出显示放疗后JNJ-1900（NBTXR 3）治疗的中位13.3个月局部无进展生存期

2025-05-05 14:11

Results demonstrated favorable safety, injection feasibility, and encouraging oncologic outcomes in patients (n=22) with locally advanced or borderline resectable pancreatic cancer
Median Overall Survival of 23 months from date of diagnosis [95% CI; 17 months – not reached]
Median Local Progression-Free Survival of 13.3 months from completion of radiation
Notable findings observed in exploratory biomarker analyses include:
- An association between increased circulating tumor mutational burden (cTMB) and LPFS and OS
- CA19-9 normalization in 59% of patients in the study, and an association between CA19-9 normalization and OS
First patient injected in a new cohort that adds standard-of-care concurrent chemotherapy (capecitabine or 5-FU) to radiotherapy-activated JNJ-1900 (NBTXR3) and recruitment is ongoing
Investigators concluded that these results support further evaluation in a randomized study